You are right Abobo, it was the wrong choice of word. As all others I am only posting my opinion.
But I think that the chance is very high that the vast majority of the 190 courses will be sold, since the article made very clear that GSK has "asked governments how much Relenza they needed" before they decided to produce 190 million courses per year !
Ref. Biota-Management I hope that they will make a much better deal for LANI than the one they made for Relenza...
This is one of the decisive points for me. I have some hope that they will be negotiating better this time, also cos they will get support from the Japanese partners.
BTA Price at posting:
$2.95 Sentiment: Hold Disclosure: Held